Abstract:OBJECTIVE:To investigate the immune response, in particular, the anti-virus cellular immune response induced by the constructed fusion DNA vaccine CRT (Calreticulin) 180/HPV6E7 in vivo and vitro.METHODS:The HPV6E7 open reading frame was amplified by polymerase chain reaction from pUC/HPV6 plasmid. The CRT180 gene was cloned by reverse transcription from human muscle tissues. The PCR products of CRT180 and HPV6E7 were subcloned into pcDNA3. 1-GFP eukaryotic vector. The recombinant plasmids CRT180/ HPV6E7 was authenticated by restrict enzyme digestion and confirmed by DNA sequencing. The DNA plasmid HPV6E7 with report gene GFP was transfected to murine B16 cells by lipofectamine kit to establish the target cells. The HPV6E7-expressing cell line was selected by G418 and identified by RT-PCR. The C57BL/6 mice were vaccinated via intramuscular injection in the right legs with 100 microg plasmid encoding CRT180-HPV6E7, CRT180 or HPV6E7, empty plasmid without insert, and PBS group respectively. The changes of the T lymphocyte subsets in the peripheral blood of the mice were evaluated by flow cytometric analysis. The lymphocytes from the spleen and lymph nodes were harvested and co-cultured with HPV6E7-expressing cell lines. The CTLs kill activity and the cytokines IL-2, IFN-gamma secretion levels of the lymphocytes were assessed by LDH and ELISA respectively.RESULTS:The constructed recombinant plasmids pcDNA3. 1-CRT180/HPV6E7, pcDNA3. 1-CRT180 and pcDNA3. 1-HPV6E7 were authenticated by restrict enzyme digestion and confirmed by DNA sequencing. Green fluorescence located in the cellular nucleus and plasma could be detected by fluorescent microscope after transfection with plasmids. The results of RT-PCR from the selected positive cell line showed the expected fragments of HPV6E7 mRNA. After immunization, the percentage of CD8+ or TCRgamma delta tau cells in the peripheral blood, the CTLs kill activity of the spleen cells and lymphocytes against HPV6E7-expressing cells, and the secretion levels of IL-2, IFN-gamma in CRT180/HPV6E7 vaccinated group increased significantly compared with the control groups (P < 0.05).CONCLUSION:Vaccination with fusion DNA vaccine CRT180/HPV6E7 could elicit a more efficient HPV6E7-specific immune response than with HPV6E7 plasmid, indicating the potential of CRT180/HPV6E7 vaccine to enhance the antigen presentation. The recombinant CRT180/HPV6E7 might help the elimination of virus in animal models and accordingly be used as a vaccine candidate in the therapy of CA.

Immune response induced in mice by attenuated Salmonella strain expressing HPV6b L1-E7 chimeric protein

The humoral and cellular immune responses induced by HPV18L1-E6/E7 DNA vaccines in mice

Tlr Agonists Activate Hpv11 E7-Pulsed Dcs to Promote A Specific T Cell Response in A Murine Model

The Specific Immune Response Elicited by Recombinant CRT120/HPV6bE7 DNA Vaccine in Mice

Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

The Construction and Immune Response of Fusion DNA Vaccine CRT180/HPV6E7

Establishment of a Cervical Cancer Model Via Inoculating SiHa Cells into Humanized Severe Combined Immunodeficient Mice.

Humoral Immune Response Induced by Co-Stimulatory Molecule B7-2 with HPV16L1 Gene

Systemic administration of a potent mouse monoclonal antibody provides multisite protection against HPV16 infection

[Development of HPV16 Positive Cervical Cancer Model in the Hu-Pbl-scid Mouse and Its Immunological Features].

Pcdnal1 Genetic Immunization Can Induce Specific Cell-Mediated Immune Responses in C57bl/6 Mice

[Construction and Immunological Evaluation of Recombinant Adenovirus Containing Codon-Modified HPV 16 L1 Gene].

Immune responses induced by DNA vaccine for local strain of human papillomavirus E7 in mice

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice

The construction of HPV16 E6 eukaryotic expression plasmid pcDNA3/E6 and its immunogenecity evaluation on animals

HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model

Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice

Induction of Cross-Neutralizing Antibodies by Sequential Immunization with Heterologous Papillomavirus L1VLPs and Its Implications for HPV Prophylactic Vaccines.

One-prime Multi-Boost Strategy Immunization with Recombinant DNA, Adenovirus, and MVA Vector Vaccines Expressing HPV16 L1 Induces Potent, Sustained, and Specific Immune Response in Mice.

Immunogenicity of the Immunodominant Cytotoxic T Lymphocyte Epitope E749-57 in HPV16 Oncoprotein E7 Chaperoned by HSP110